Condition

Advanced Malignancies clinical trials and research

• 12Clinical trials
• 13Countries

Newest Advanced Malignancies clinical trials

All recruiting trials (12)

• GPC3-targeted ADC for advanced solid tumors

  This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 7 other locations · NCT07730190

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• PM54 plus immunotherapy in adults with advanced cancer

  This trial tests PM54 together with pembrolizumab to see if it is safe and tolerable and to see if it helps shrink or stabilize tumors in adults with advanced cancers.

  Recruiting at 11 sites Phase 1/2 PharmaMar · New York, New York and 10 other locations · NCT07644039

• PF-07994525 in advanced cancers: a first-in-human dose-escalation study

  A single-arm, early-phase study tests PF-07994525 in adults with advanced cancers who have exhausted other therapies to see if it’s safe and shows any signs of tumor activity.

  Recruiting at 29 sites Phase 1 Pfizer · Denver, Colorado and 29 other locations · NCT07426757

• Pelabresib drug interactions with common meds in advanced cancer

  This study tests how pelabresib affects the body’s handling of repaglinide, midazolam, and the combined oral contraceptive in adults with advanced cancers.

  Recruiting at 6 sites Phase 1 Novartis · Bordeaux and 5 other locations · NCT07340190

• BR111-101 treatment for advanced cancers

  This Phase 1 test will try BR111-101 injections in adults with advanced solid tumors or relapsed/refractory B-cell lymphoma who have run out of or cannot tolerate standard treatments.

  Recruiting Phase 1 BioRay Pharmaceutical Co., Ltd. · Shanghai, Pudong New Area · NCT06937957

• Combining IBI363 with Bevacizumab or Furuitinib for Advanced Colorectal Cancer

  This study is testing if a new drug called IBI363, when combined with either Bevacizumab or Furuitinib, can help adults with advanced colorectal cancer who haven't responded to standard treatments.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06717880

• Evaluating IBI363 for patients with advanced cancers

  This study is testing a new treatment called IBI363 combined with chemotherapy to see if it helps people with advanced cancers who haven't responded to standard treatments.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT06468098

• Continued treatment with pelabresib for patients from previous studies

  This study is testing whether continued treatment with pelabresib can help people who have already tried it in earlier studies stay healthy and live longer without leukemia.

  Recruiting at 15 sites Phase 3 Novartis · Los Angeles, California and 14 other locations · NCT06401356

• Treatment with TQB2930 for advanced breast cancer

  This study is testing a new treatment called TQB2930 for people with advanced breast cancer to see if it is safe and effective, both on its own and when combined with other chemotherapy drugs.

  Recruiting at 2 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT06202261

• BRY812 injection for adults with advanced cancers

  This trial will test BRY812 injection in adults with advanced solid tumors that have not responded to standard treatments to see if it is safe and helps control cancer.

  Recruiting Phase 1 BioRay Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06038058

• Testing BI-1808 alone and with pembrolizumab for advanced cancers

  This study is testing a new cancer treatment called BI-1808, both alone and with another drug called pembrolizumab, to see if it is safe and effective for people with advanced cancers that haven't responded to other treatments.

  Recruiting at 18 sites Phase 1/2 BioInvent International AB · Duarte, California and 24 other locations · NCT04752826

Related topics

Quick answers

How many Advanced Malignancies clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in China (6 trials), United States (4 trials), Spain (4 trials), United Kingdom (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 7, Phase 1/2: 3, Phase 3: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →